These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33367834)

  • 1. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration.
    Jafar-Nejad P; Powers B; Soriano A; Zhao H; Norris DA; Matson J; DeBrosse-Serra B; Watson J; Narayanan P; Chun SJ; Mazur C; Kordasiewicz H; Swayze EE; Rigo F
    Nucleic Acids Res; 2021 Jan; 49(2):657-673. PubMed ID: 33367834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier.
    Barker SJ; Thayer MB; Kim C; Tatarakis D; Simon MJ; Dial R; Nilewski L; Wells RC; Zhou Y; Afetian M; Akkapeddi P; Chappell A; Chew KS; Chow J; Clemens A; Discenza CB; Dugas JC; Dwyer C; Earr T; Ha C; Ho YS; Huynh D; Lozano EI; Jayaraman S; Kwan W; Mahon C; Pizzo M; Robles-Colmenares Y; Roche E; Sanders L; Stergioulis A; Tong R; Tran H; Zuchero Y; Estrada AA; Gadkar K; Koth CMM; Sanchez PE; Thorne RG; Watts RJ; Sandmann T; Kane LA; Rigo F; Dennis MS; Lewcock JW; DeVos SL
    Sci Transl Med; 2024 Aug; 16(760):eadi2245. PubMed ID: 39141703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-cell map of antisense oligonucleotide activity in the brain.
    Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
    Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.
    Rigo F; Chun SJ; Norris DA; Hung G; Lee S; Matson J; Fey RA; Gaus H; Hua Y; Grundy JS; Krainer AR; Henry SP; Bennett CF
    J Pharmacol Exp Ther; 2014 Jul; 350(1):46-55. PubMed ID: 24784568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
    Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
    Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
    Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.
    Hua Y; Sahashi K; Hung G; Rigo F; Passini MA; Bennett CF; Krainer AR
    Genes Dev; 2010 Aug; 24(15):1634-44. PubMed ID: 20624852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
    Kim TW; Kim KS; Seo JW; Park SY; Henry SP
    J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
    Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
    Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.
    Mazur C; Powers B; Zasadny K; Sullivan JM; Dimant H; Kamme F; Hesterman J; Matson J; Oestergaard M; Seaman M; Holt RW; Qutaish M; Polyak I; Coelho R; Gottumukkala V; Gaut CM; Berridge M; Albargothy NJ; Kelly L; Carare RO; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
    JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31619586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy.
    Hammond SM; Abendroth F; Goli L; Stoodley J; Burrell M; Thom G; Gurrell I; Ahlskog N; Gait MJ; Wood MJ; Webster CI
    JCI Insight; 2022 Dec; 7(24):. PubMed ID: 36346674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
    Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system.
    Sullivan JM; Mazur C; Wolf DA; Horky L; Currier N; Fitzsimmons B; Hesterman J; Pauplis R; Haller S; Powers B; Tayefeh L; DeBrosse-Serra B; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
    J Transl Med; 2020 Aug; 18(1):309. PubMed ID: 32771027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264.
    Poletti A; Fischbeck KH
    J Neurochem; 2020 Apr; 153(2):146-149. PubMed ID: 32056234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct intraventricular delivery of drugs to the rodent central nervous system.
    DeVos SL; Miller TM
    J Vis Exp; 2013 May; (75):e50326. PubMed ID: 23712122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.